CU24554B1 - Proteínas de fusión compuestas por una muteína de interleucina 2 e interferón tipo 1 - Google Patents

Proteínas de fusión compuestas por una muteína de interleucina 2 e interferón tipo 1

Info

Publication number
CU24554B1
CU24554B1 CU2018000039A CU20180039A CU24554B1 CU 24554 B1 CU24554 B1 CU 24554B1 CU 2018000039 A CU2018000039 A CU 2018000039A CU 20180039 A CU20180039 A CU 20180039A CU 24554 B1 CU24554 B1 CU 24554B1
Authority
CU
Cuba
Prior art keywords
fusion proteins
mutein
interferon
type
interleukin
Prior art date
Application number
CU2018000039A
Other languages
English (en)
Other versions
CU20180039A7 (es
Inventor
Molina Luis Enrique Fernández
García Tays Hernández
Hernández Giselle Hevia
Monzón Kalet León
Pardillo Circe Mesa
Chediak Maura Lisett Rábade
Original Assignee
Ct Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Inmunologia Molecular filed Critical Ct Inmunologia Molecular
Priority to CU2018000039A priority Critical patent/CU24554B1/es
Priority to US17/052,912 priority patent/US11926654B2/en
Priority to PCT/CU2019/050003 priority patent/WO2019214757A1/es
Priority to JP2021512997A priority patent/JP7423607B2/ja
Priority to BR112020022511-8A priority patent/BR112020022511A2/pt
Priority to CN201980031020.6A priority patent/CN112218884A/zh
Priority to EP19729611.4A priority patent/EP3792277A1/en
Priority to CA3098653A priority patent/CA3098653A1/en
Priority to TW108115578A priority patent/TWI821287B/zh
Priority to ARP190101204A priority patent/AR115083A1/es
Publication of CU20180039A7 publication Critical patent/CU20180039A7/es
Publication of CU24554B1 publication Critical patent/CU24554B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

<p>La presente invención se relaciona con el campo de Ia Biotecnología y Ia lnmunooncología. Se describen proteínas de fusión basadas en citocinas, denominadas bicitocinas, particularmente formadas por Ia unión de una muteína agonista de IL2 con un interferón tipo 1, enlazados mediante Ia región Fc de una lgG1 humana mutada y un péptido conector. Se describen, además, las composiciones farmacéuticas que comprenden como principio activo las proteínas de fusión aquí descritas.</p>
CU2018000039A 2018-05-07 2018-05-07 Proteínas de fusión compuestas por una muteína de interleucina 2 e interferón tipo 1 CU24554B1 (es)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CU2018000039A CU24554B1 (es) 2018-05-07 2018-05-07 Proteínas de fusión compuestas por una muteína de interleucina 2 e interferón tipo 1
US17/052,912 US11926654B2 (en) 2018-05-07 2019-03-05 Fusion proteins composed of an interleukin-2 mutein and type I interferon
PCT/CU2019/050003 WO2019214757A1 (es) 2018-05-07 2019-05-03 Proteínas de fusión compuestas por una muteina de interleucina-2 e interferon tipo 1
JP2021512997A JP7423607B2 (ja) 2018-05-07 2019-05-03 インターロイキン ２突然変異タンパク質およびｉ型インターフェロンで構成される融合タンパク質
BR112020022511-8A BR112020022511A2 (pt) 2018-05-07 2019-05-03 proteínas de fusão compostas por uma muteína de interleucina-2 (il-2) e interferon do tipo i
CN201980031020.6A CN112218884A (zh) 2018-05-07 2019-05-03 由白介素-2突变蛋白和i型干扰素构成的融合蛋白
EP19729611.4A EP3792277A1 (en) 2018-05-07 2019-05-03 Fusion proteins composed of an interleukin-2 mutein and type i interferon
CA3098653A CA3098653A1 (en) 2018-05-07 2019-05-03 Fusion proteins composed of an interleukin-2 mutein and type i interferon
TW108115578A TWI821287B (zh) 2018-05-07 2019-05-06 介白素－２突變形成之蛋白質與第ｉ型干擾素所構成之融合蛋白質
ARP190101204A AR115083A1 (es) 2018-05-07 2019-05-07 Proteínas de fusión compuestas por una muteína de interleucina 2 e interferón tipo 1

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2018000039A CU24554B1 (es) 2018-05-07 2018-05-07 Proteínas de fusión compuestas por una muteína de interleucina 2 e interferón tipo 1

Publications (2)

Publication Number Publication Date
CU20180039A7 CU20180039A7 (es) 2019-12-03
CU24554B1 true CU24554B1 (es) 2021-11-04

Family

ID=68467792

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2018000039A CU24554B1 (es) 2018-05-07 2018-05-07 Proteínas de fusión compuestas por una muteína de interleucina 2 e interferón tipo 1

Country Status (10)

Country Link
US (1) US11926654B2 (es)
EP (1) EP3792277A1 (es)
JP (1) JP7423607B2 (es)
CN (1) CN112218884A (es)
AR (1) AR115083A1 (es)
BR (1) BR112020022511A2 (es)
CA (1) CA3098653A1 (es)
CU (1) CU24554B1 (es)
TW (1) TWI821287B (es)
WO (1) WO2019214757A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020023118A2 (pt) 2018-05-14 2021-04-13 Werewolf Therapeutics, Inc. Polipeptídeos de interleucina 12 ativáveis e métodos de uso destes
AU2019271148B9 (en) 2018-05-14 2025-05-29 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
EP3856764A4 (en) 2018-09-27 2022-11-02 Xilio Development, Inc. MASKED CYTOKINE POLYPEPTIDES
WO2020232305A1 (en) 2019-05-14 2020-11-19 Werewolf Therapeutics, Inc. Separation moieties and methods and use thereof
EP4058471A1 (en) 2019-11-14 2022-09-21 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
US12091440B2 (en) 2019-12-20 2024-09-17 Regeneron Pharmaceuticals, Inc. IL2 and peptide-MHC complex fusion proteins and methods of use thereof
JP2023534793A (ja) * 2020-07-09 2023-08-14 ユーティレックス カンパニー リミテッド Ｉｌ－２バリアント
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
KR20230113581A (ko) 2020-11-25 2023-07-31 실리오 디벨럽먼트, 인크. 종양 특이적 절단성 링커
TW202317623A (zh) 2021-06-14 2023-05-01 美商再生元醫藥公司 基於il2之治療劑及其使用方法
US20230303650A1 (en) * 2022-01-21 2023-09-28 Aetio Biotherapy, Inc. Immunoconjugates of Interlukin-2 Mutant Polypeptides with Antibodies
CN114853909A (zh) * 2022-05-13 2022-08-05 南京吉盛澳玛生物医药有限公司 新型IL-2与INFα和Fc融合蛋白的设计、制备及用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610830B1 (en) * 1980-07-01 2003-08-26 Hoffman-La Roche Inc. Microbial production of mature human leukocyte interferons
CZ20014123A3 (cs) * 1999-05-19 2002-06-12 Lexigen Pharmaceuticals Corp. Exprese a export interferonů-alfa jako Fc fúzních proteinů
JP4793971B2 (ja) * 1999-08-09 2011-10-12 メルク パテント ゲーエムベーハー 複合サイトカイン−抗体複合体
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
WO2009152610A1 (en) 2008-06-20 2009-12-23 The Royal Institution For The Advancement Of Learning/Mcgill University Interleukin-2/soluble tgf-beta type ii receptor b conjugates and methods and uses thereof
CN102041263B (zh) * 2010-02-08 2013-01-09 河南省动物疫病预防控制中心 鸡α干扰素/白细胞介素2嵌合基因
CU23923B1 (es) * 2010-11-12 2013-07-31 Ct De Inmunología Molecular Polipéptidos derivados de la il-2 con actividad agonista
WO2012088446A1 (en) * 2010-12-22 2012-06-28 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
TW201315742A (zh) * 2011-09-26 2013-04-16 Novartis Ag 治療代謝病症之雙功能蛋白質
WO2014100014A1 (en) * 2012-12-17 2014-06-26 The Board Of Trustees Of The Leland Stanford Junior University Super-2 complexes with antibody to augment il-2 therapy
CN104877029A (zh) * 2015-04-24 2015-09-02 昆明理工大学 一种Vimentin-Fc融合蛋白及其应用
CN106397607A (zh) * 2016-09-13 2017-02-15 河南师范大学 重组人成纤维细胞生长因子21融合蛋白及其在制备治疗代谢疾病药物中的应用
CN107286254A (zh) * 2017-08-09 2017-10-24 芜湖英特菲尔生物制品产业研究院有限公司 犬白蛋白‑干扰素α‑白介素2融合蛋白、制备方法及其编码基因、一种犬长效干扰素
CN107245108A (zh) * 2017-08-09 2017-10-13 芜湖英特菲尔生物制品产业研究院有限公司 牛白蛋白‑干扰素α‑白介素2融合蛋白、制备方法及其编码基因、一种牛长效干扰素

Also Published As

Publication number Publication date
AR115083A1 (es) 2020-11-25
US20210238246A1 (en) 2021-08-05
CN112218884A (zh) 2021-01-12
WO2019214757A1 (es) 2019-11-14
CA3098653A1 (en) 2019-11-14
JP7423607B2 (ja) 2024-01-29
BR112020022511A2 (pt) 2021-02-09
TWI821287B (zh) 2023-11-11
TW202014431A (zh) 2020-04-16
JP2021522861A (ja) 2021-09-02
US11926654B2 (en) 2024-03-12
CU20180039A7 (es) 2019-12-03
EP3792277A1 (en) 2021-03-17

Similar Documents

Publication Publication Date Title
CU24554B1 (es) Proteínas de fusión compuestas por una muteína de interleucina 2 e interferón tipo 1
PE20251254A1 (es) Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer
PE20230849A1 (es) PROTEINAS DE FUSION INTERLEUCINA-2-Fc Y METODOS DE USO
CO2017002166A2 (es) Proteínas de fusión de interleucina 2 / receptor de interleucina-2 alfa
UA129709C2 (uk) ПОЛІПЕПТИД З ПРОТЕАЗНОЮ АКТИВНІСТЮ IdeS
MX386014B (es) Citocina fusionada a fc heterodimérico, y composición farmacéutica que comprende la misma.
MX2021008144A (es) Composiciones para aumentar la media vida de un agente terapeutico en caninos y metodos de uso.
MX2022008771A (es) Metodos y composiciones de muteinas de il2 sesgadas.
EA201792250A1 (ru) Мутеины интерлейкина-2 для роста регуляторных т-клеток
PH12020551026A1 (en) Fusion protein comprising il-2 protein and cd80 protein, and use thereof
MA38477B1 (fr) Mutéines d&#39;interleukine 2 pour la propagation de lymphocytes t régulateurs
HRP20220960T1 (hr) Kimerni proteini faktora viii i njihova upotreba
PE20161324A1 (es) Proteinas de fusion de interleucina-2 y usos de las mismas
PE20141551A1 (es) Proteinas de fusion para tratar trastornos metabolicos
AR103714A1 (es) Proteínas específicas para pioverdina y pioquelina
JOP20210326A1 (ar) أجسام مضادة للمستقبل 1 لببتيد إدرار الصوديوم في البول وطرق استخدامها
MX381726B (es) Cadena alfa del receptor de inmunoglobulina e (ige) de alta afinidad de fusion de fragmento cristalizable (fc).
CO2023000048A2 (es) Conjugados de citoquina
BR112022005426A2 (pt) Polipeptídeos de fusão dap10/dap12
CL2019003459A1 (es) Métodos de cultivo celular.
MX2018013177A (es) Proteina de fusion que contiene variante ccl3 y uso de la misma referencia cruzada para aplicaciones relacionadas.
MX2023009405A (es) Muteinas de interleuquina 2 para la expansion de celulas t regulatorias.
EP4435011A4 (en) FUSION PROTEIN CONSTRUCTION TAKING INTERLEUKIN 15 AS ACTIVE INGREDIENT AND USE THEREOF
EP3904375A4 (en) Type 1 interferon neutralizing fc-fusion protein and use thereof
AR133519A1 (es) PROTEÍNAS Fc HETERODIMÉRICAS DE INTERLEUCINA 12 (IL-12) MONOVALENTES